Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated, commercial-stage biopharmaceutical company, announced it will deliver an oral presentation on its investigational TNX-801 vaccine platform and lead a working group session at the World Vaccine Congress Europe, scheduled for Oct. 19-21, 2026, in Amsterdam, Netherlands. The presentation, set for Oct. 21 at 1:15 p.m. CEST, will address the safety and efficacy of TNX-801, a live, attenuated, minimally replicative horsepox virus-based vaccine platform being developed to protect against mpox and other infectious diseases.
The company will also lead a working group session titled “Vectored Vaccine Platforms: From Design to Improving Efficacy” on Oct. 20 at 11:30 a.m. CEST. This participation underscores Tonix’s commitment to advancing vaccine technology amid growing global concerns over mpox outbreaks and the need for new prophylactic options.
Tonix Pharmaceuticals is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA(TM) (cyclobenzaprine HCl sublingual tablets 2.8mg), the company’s recently approved flagship medicine, is the first new treatment for fibromyalgia in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace(R) SymTouch(R) and Tosymra(R).
Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. In addition, the company’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
These product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. The latest news and updates relating to TNXP are available in the company’s newsroom at https://ibn.fm/TNXP. For a full view of the press release, visit https://ibn.fm/BHVjU.
The World Vaccine Congress Europe is a significant platform for companies like Tonix to share research and collaborate with global health stakeholders. Tonix’s presentation on TNX-801 could impact the development of next-generation vaccines, especially as the world seeks robust defenses against mpox and other infectious diseases. The working group session will further facilitate knowledge exchange on vectored vaccine platforms, potentially accelerating innovation in the field.
Investors and industry watchers will be keen to see how Tonix’s vaccine platform progresses, given the company’s diverse pipeline and commercial-stage status. The event may also shine a light on Tonix’s broader immunology efforts, which include programs for Lyme disease and transplant rejection. As the biotech sector continues to evolve, Tonix’s participation in such a prominent congress highlights its role in addressing unmet medical needs.
BioMedWire, a specialized communications platform, is covering this development. For more information, visit BioMedWire or IBN, which offers corporate communications solutions and social media distribution.
